Larisa H Cavallari1, Craig R Lee2,3, Julio D Duarte4,5, Edith A Nutescu6,5, Kristin W Weitzel7, George A Stouffer8, Julie A Johnson7. 1. Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, FL. lcavallari@cop.ufl.edu. 2. Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC. 3. Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC. 4. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL. 5. Personalized Medicine Program, University of Illinois Hospital and Health Science System, Chicago, IL. 6. Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL. 7. Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, FL. 8. Division of Cardiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
PURPOSE: The operational elements essential for establishing an inpatient pharmacogenetic service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug therapy in pharmacogenetics programs at three institutions is highlighted. SUMMARY: Pharmacists are well positioned to assume important roles in facilitating the clinical use of genetic information to optimize drug therapy given their expertise in clinical pharmacology and therapeutics. Pharmacists have assumed important roles in implementing inpatient pharmacogenetics programs. This includes programs designed to incorporate genetic test results to optimize antiplatelet drug selection after percutaneous coronary intervention and personalize warfarin dosing. Pharmacist involvement occurs on many levels, including championing and leading pharmacogenetics implementation efforts, establishing clinical processes to support genotype-guided therapy, assisting the clinical staff with interpreting genetic test results and applying them to prescribing decisions, and educating other healthcare providers and patients on genomic medicine. The three inpatient pharmacogenetics programs described use reactive versus preemptive genotyping, the most feasible approach under the current third-party payment structure. All three sites also follow Clinical Pharmacogenetics Implementation Consortium guidelines for drug therapy recommendations based on genetic test results. CONCLUSION: With the clinical emergence of pharmacogenetics into the inpatient setting, it is important that pharmacists caring for hospitalized patients are well prepared to serve as experts in interpreting and applying genetic test results to guide drug therapy decisions. Since genetic test results may not be available until after patient discharge, pharmacists practicing in the ambulatory care setting should also be prepared to assist with genotype-guided drug therapy as part of transitions in care.
PURPOSE: The operational elements essential for establishing an inpatient pharmacogenetic service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug therapy in pharmacogenetics programs at three institutions is highlighted. SUMMARY: Pharmacists are well positioned to assume important roles in facilitating the clinical use of genetic information to optimize drug therapy given their expertise in clinical pharmacology and therapeutics. Pharmacists have assumed important roles in implementing inpatient pharmacogenetics programs. This includes programs designed to incorporate genetic test results to optimize antiplatelet drug selection after percutaneous coronary intervention and personalize warfarin dosing. Pharmacist involvement occurs on many levels, including championing and leading pharmacogenetics implementation efforts, establishing clinical processes to support genotype-guided therapy, assisting the clinical staff with interpreting genetic test results and applying them to prescribing decisions, and educating other healthcare providers and patients on genomic medicine. The three inpatient pharmacogenetics programs described use reactive versus preemptive genotyping, the most feasible approach under the current third-party payment structure. All three sites also follow Clinical Pharmacogenetics Implementation Consortium guidelines for drug therapy recommendations based on genetic test results. CONCLUSION: With the clinical emergence of pharmacogenetics into the inpatient setting, it is important that pharmacists caring for hospitalized patients are well prepared to serve as experts in interpreting and applying genetic test results to guide drug therapy decisions. Since genetic test results may not be available until after patient discharge, pharmacists practicing in the ambulatory care setting should also be prepared to assist with genotype-guided drug therapy as part of transitions in care.
Authors: L L Leape; T A Brennan; N Laird; A G Lawthers; A R Localio; B A Barnes; L Hebert; J P Newhouse; P C Weiler; H Hiatt Journal: N Engl J Med Date: 1991-02-07 Impact factor: 91.245
Authors: Kristin W Weitzel; Amanda R Elsey; Taimour Y Langaee; Benjamin Burkley; David R Nessl; Aniwaa Owusu Obeng; Benjamin J Staley; Hui-Jia Dong; Robert W Allan; J Felix Liu; Rhonda M Cooper-Dehoff; R David Anderson; Michael Conlon; Michael J Clare-Salzler; David R Nelson; Julie A Johnson Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-10 Impact factor: 3.908
Authors: James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-11 Impact factor: 3.908
Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas Journal: Blood Date: 2008-06-23 Impact factor: 22.113
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875
Authors: Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson Journal: Curr Drug Metab Date: 2014-02 Impact factor: 3.731
Authors: John Valgus; Kristin W Weitzel; Josh F Peterson; Daniel J Crona; Christine M Formea Journal: Am J Health Syst Pharm Date: 2019-04-08 Impact factor: 2.637
Authors: Tristan M Sissung; Jon W McKeeby; Jharana Patel; Juan J Lertora; Parag Kumar; Willy A Flegel; Sharon D Adams; Ellen J Eckes; Frank Mickey; Teri M Plona; Stephanie D Mellot; Ryan N Baugher; Xiaolin Wu; Daniel R Soppet; Mary E Barcus; Vivekananda Datta; Kristen M Pike; Gary DiPatrizio; William D Figg; Barry R Goldspiel Journal: J Clin Pharmacol Date: 2017-10 Impact factor: 3.126
Authors: Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee Journal: Clin Pharmacol Ther Date: 2018-01-30 Impact factor: 6.875
Authors: Nicholas J Keeling; Tyler J Dunn; John P Bentley; Sujith Ramachandran; James M Hoffman; Meagen Rosenthal Journal: Genet Med Date: 2021-04-29 Impact factor: 8.822
Authors: Benjamin Q Duong; Meghan J Arwood; J Kevin Hicks; Amber L Beitelshees; Francesco Franchi; John T Houder; Nita A Limdi; Kelsey J Cook; Aniwaa Owusu Obeng; Natasha Petry; Sony Tuteja; Amanda R Elsey; Larisa H Cavallari; Kristin Wiisanen Journal: Pharmgenomics Pers Med Date: 2020-07-17